Search
Search
About
Log in
Join
Experiences with
Obinutuzumab
Posts
Communities
357 public posts
Filter results
Chemo makes resistant cancer stem cells???
et_cid=4472513&et_rid=741277821&type=cta The research involves breast cancer and the resistance is referred to as from "chemotherapy" so I wonder if the finding of resistance would be applicable to all therapies i.e. immunotherapies (CD20 mAbs like Rituxan, Ofatumumab,
Obinutuzumab
etc), Kinase inhibitors
et_cid=4472513&et_rid=741277821&type=cta The research involves breast cancer and the resistance is referred to as from "chemotherapy" so I wonder if the finding of resistance would be applicable to all therapies i.e. immunotherapies (CD20 mAbs like Rituxan, Ofatumumab,
Obinutuzumab
etc), Kinase inhibitors
ThreeWs
in
CLL Support
10 years ago
Dr Sharman's survey to assess the CLL community's understanding of new treatments is now closed
Dr Jeff Sharman is curious to understand what people know / think they know about the new drugs Ibrutinib, Idelalisib and
obinutuzumab
. His latest blog was a 10 question survey (now closed) to gain CLL community feedback, the results of which he plans to use to help shape future his blog posts.
Dr Jeff Sharman is curious to understand what people know / think they know about the new drugs Ibrutinib, Idelalisib and
obinutuzumab
. His latest blog was a 10 question survey (now closed) to gain CLL community feedback, the results of which he plans to use to help shape future his blog posts.
AussieNeil
Partner
in
CLL Support
10 years ago
Ibrutinib monotherapy Clinical Trial latest monitoring - month 40
Another patient was on a Trial Protocol with
Obinutuzumab
& TRU-16. This patient was doing quite well and was very pleased so far. I urged this patient to think about joining one or more of the several CLL forums to share and learn.
Another patient was on a Trial Protocol with
Obinutuzumab
& TRU-16. This patient was doing quite well and was very pleased so far. I urged this patient to think about joining one or more of the several CLL forums to share and learn.
ThreeWs
in
CLL Support
10 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
ASCO 2014: Dr. Kipps Discusses Targeted Therapy and Obinutuzumab
Kipps Discusses Targeted Therapy and
Obinutuzumab
in the Treatment of CLL (chronic lymphocytic leukemia) in my latest blog post at http://bkoffman.blogspot.com where I reference the latest research and the data from ASH last December.
Kipps Discusses Targeted Therapy and
Obinutuzumab
in the Treatment of CLL (chronic lymphocytic leukemia) in my latest blog post at http://bkoffman.blogspot.com where I reference the latest research and the data from ASH last December.
bkoffman
CLL CURE Hero
in
CLL Support
10 years ago
ASH 2013: Dr. Byrd on the New Data on Ibrutinib and Obinutuzumub in CLL.
We go into some detail, especially about
obinutuzumab
. See: http://bkoffman.blogspot.com Brian
We go into some detail, especially about
obinutuzumab
. See: http://bkoffman.blogspot.com Brian
bkoffman
CLL CURE Hero
in
CLL Support
10 years ago
LATE ONSET NEUTROPENIA MAY BE A COMPLICATION OF FCR (or rituximab, obinutuzumab or other anti-CD20 monoclonal antibody infusions - Admin)
These data suggest that LON after
obinutuzumab
treatment is as common as with rituximab.
These data suggest that LON after
obinutuzumab
treatment is as common as with rituximab.
zevkalman
in
CLL Support
10 years ago
Australians - here's your opportunity to support the listing of GAZYVA (Obinutuzimab) on the PBS - Deadline is Wed 11th June!
Horwitz, MD, Memorial Sloan Kettering Cancer Center in 2014-NCCN-Guideline-Updates [i]“The most significant changes are the addition of two newly approved agents for chronic lymphocytic leukemia,
obinutuzumab
and ibrutinib. That’s quite a lot in a single year.
Horwitz, MD, Memorial Sloan Kettering Cancer Center in 2014-NCCN-Guideline-Updates [i]“The most significant changes are the addition of two newly approved agents for chronic lymphocytic leukemia,
obinutuzumab
and ibrutinib. That’s quite a lot in a single year.
AussieNeil
Partner
in
CLL Support
10 years ago
GAZYVA® (Obinutuzumab) gains TGA approval for 1st line treatment of CLL in combination with Chlorambucil in Australia
https://healthunlocked.com/cllsupport/posts/130022663/
obinutuzumab
-ga101-delayed-disease-progression-longer-than-mabthera-rituxan-roche-press-release-on-cll11-study Neil Picture shows some lichen on a native shrub
https://healthunlocked.com/cllsupport/posts/130022663/
obinutuzumab
-ga101-delayed-disease-progression-longer-than-mabthera-rituxan-roche-press-release-on-cll11-study Neil Picture shows some lichen on a native shrub
AussieNeil
Partner
in
CLL Support
10 years ago
ASH 2013: Dr. Jennifer Brown Discusses the New Data on Obinutuzumab (GA-101 or Gazyva)
Brown from ASH 2013 she gives a nice summary and not only how better
Obinutuzumab
is than Rituximab, but also why to is better, and what this might mean down the line. See: http://bkoffman.blogspot.com for the video interview.
Brown from ASH 2013 she gives a nice summary and not only how better
Obinutuzumab
is than Rituximab, but also why to is better, and what this might mean down the line. See: http://bkoffman.blogspot.com for the video interview.
bkoffman
CLL CURE Hero
in
CLL Support
11 years ago
Obinutuzumab was approved for treatment naive patients, but in only in combination with chlorambucil.
Friends
Obinutuzumab
was approved for treatment naive patients, but in only in combination with chlorambucil. That is a very limited indication and I don't like that You might want to read my blog commentary on the issues swirling around this FDA decision.
Friends
Obinutuzumab
was approved for treatment naive patients, but in only in combination with chlorambucil. That is a very limited indication and I don't like that You might want to read my blog commentary on the issues swirling around this FDA decision.
bkoffman
CLL CURE Hero
in
CLL Support
11 years ago
Obinutuzumab (GA101) delayed disease progression longer than MabThera/Rituxan - Roche press release on CLL11 study
"At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to MabThera/Rituxan plus
"At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to MabThera/Rituxan plus
AussieNeil
Partner
in
CLL Support
11 years ago
Obinutuzumab likely first new kid on the block...
http://www.gene.com/media/press-releases/14487/2013-07-02/fda-grants-genentechs-
obinutuzumab
-ga101 ~chris
http://www.gene.com/media/press-releases/14487/2013-07-02/fda-grants-genentechs-
obinutuzumab
-ga101 ~chris
Cllcanada
Top Poster CURE Hero
in
CLL Support
11 years ago
Obinutuzumab Active in Elderly Chronic Lymphocytic Leukemia
"This finding suggests an 86% reduction in the risk for a progression, relapse, or death in the
obinutuzumab
arm," Dr. Goede pointed out.
"This finding suggests an 86% reduction in the risk for a progression, relapse, or death in the
obinutuzumab
arm," Dr. Goede pointed out.
Cllcanada
Top Poster CURE Hero
in
CLL Support
11 years ago
Promising clinical results for new drug combination for CLL (GA101 plus Chlorambucil)
"
Obinutuzumab
is the first 'second generation' monoclonal antibody and it appears to be significantly more effective than earlier versions.
"
Obinutuzumab
is the first 'second generation' monoclonal antibody and it appears to be significantly more effective than earlier versions.
HAIRBEAR_UK
Administrator
in
CLL Support
11 years ago
CLL - a Cancer of the Immune System
temperature should be treated seriously, particularly if you are having treatment or have been treated with a CD20 monoclonal antibody such as Rituximab/Rituxan/Mabthera,
Obinutuzumab
/Gazyva or Ofatumumab/Arzerra within the last year, where you may be experiencing Late Onset Neutropenia https://healthunlocked.com
temperature should be treated seriously, particularly if you are having treatment or have been treated with a CD20 monoclonal antibody such as Rituximab/Rituxan/Mabthera,
Obinutuzumab
/Gazyva or Ofatumumab/Arzerra within the last year, where you may be experiencing Late Onset Neutropenia https://healthunlocked.com
AussieNeil
Partner
in
CLL Support
11 years ago
Winners And Losers in CLL at ASCO '13 - a marketing strategy consultant's perspective
He covers in particular how the new drugs by Gilead Sciences (idelalisib), Roche (
Obinutuzumab
- GA101), Infinity Pharmaceuticals (IPI-145), AbbVie (with Roche) (ABT-199), Pharmacyclics and Johnson & Johnson (Ibrutinib) fared in their ASCO presentations and which companies with CLL drug development in
He covers in particular how the new drugs by Gilead Sciences (idelalisib), Roche (
Obinutuzumab
- GA101), Infinity Pharmaceuticals (IPI-145), AbbVie (with Roche) (ABT-199), Pharmacyclics and Johnson & Johnson (Ibrutinib) fared in their ASCO presentations and which companies with CLL drug development in
AussieNeil
Partner
in
CLL Support
11 years ago
Genentech has announced an Expanded Access Program (EAP) for Obinutuzumab (GA101)
http://www.gene.com/media/press-releases/14427/2013-05-15/genentechs-
obinutuzumab
-ga101-significan
http://www.gene.com/media/press-releases/14427/2013-05-15/genentechs-
obinutuzumab
-ga101-significan
Cllcanada
Top Poster CURE Hero
in
CLL Support
11 years ago
1
...
17
18
10
Filter results
Clear filters
Posted in
All communities
CLL Support
337 results
CLL America Support
5 results
Leukaemia Support
4 results
View top 10 communities
Sort by
Most Relevant
Newest